(Health-NewsWire.Net, October 04, 2017 ) According to Publisher, the Global Erythropoietin Drug Market is accounted for $8.04 billion in 2016 and is expected to reach $14.4 billion by 2022 growing at a CAGR of 10.2% from 2016 to 2022. Rising number of chronic kidney diseases (CKD) and dialysis patient pools are the major drivers for the market. Moreover, increasing cases of cancer, HIV's and ESRD (End Stage Renal Diseases) are some of the factors enhancing the market growth. However, growing competition from substitute drugs and rising threats from thrombosis and PRCA are the factors inhibiting the market size.
For more information about this report: http://www.reportsweb.com/erythropoietin-drug-global-market-outlook-2016-2022 By Application, anemia segment leads the Erythropoietin Drugs market during the forecast period. On the other hand, retail pharmacies in end user segment dominated the global market with a huge market share. In terms of geography, Europe commanded the maximum market share and will continue to dominate the market over the forecast period.
Some of the key players in the market include Johnson and Johnson, Hospira, Inc., F. Hoffmann-La Roche AG, Amgen Inc, Kyowa Hakko Kirin Co., Ltd, 3SBio Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Intas Pharmaceuticals, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries, JCR Pharmaceuticals, LG Life Science, Novartis AG, Shenyang Sunshine Pharmaceutical, Sihuan Pharmaceutical, Uni-Bio Science, Wanbang Biochemical Pharmaceuticals, Pfizer Inc., Chugai Pharmaceutical and Dragon Pharma.
Products Covered: -Biosimilars -Epoetin-Alfa -Epoetin-Beta -Darbepoietin-Alfa -Other Biosimilar Products -Biologics -Epoetin-Zeta -Epoetin-Omega -Other Biologic Products
Drugs Covered: -Biosimilar Drug -Xue Da Sheng -HEMAX -Abseamed -Retacrit -Epoetin-alfa BS -EPIAO -Binocrit -Other Biosimilar Drugs -Biologic Drug -Aranesp -Mircera -Procrit -NeoRecromon -Eprex -Epogen -Other Biologic Drugs
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001716562/sample
Applications Covered: -Anemia -HIV -End Stage Renal Disease -Cancer -Dialysis -Oncology Diseases -Other Applications
End Users Covered: -Retail Pharmacies -Hospital -Other End Users
Regions Covered: -North America -US -Canada -Mexico -Europe -Germany -France -Italy -UK -Spain -Rest of Europe -Asia Pacific -Japan -China -India -Australia -New Zealand -Rest of Asia Pacific -Rest of the World -Middle East -Brazil -Argentina -South Africa -Egypt
Company Profiling 11.1 Johnson and Johnson 11.2 Hospira, Inc. 11.3 F. Hoffmann-La Roche AG 11.4 Amgen Inc 11.5 Kyowa Hakko Kirin Co., Ltd 11.6 3SBio Inc. 11.7 Boehringer Ingelheim Pharmaceuticals, Inc. 11.8 Intas Pharmaceuticals 11.9 Dr. Reddy's Laboratories 11.10 Teva Pharmaceutical Industries 11.11 JCR Pharmaceuticals 11.12 LG Life Science 11.13 Novartis AG 11.14 Shenyang Sunshine Pharmaceutical 11.15 Sihuan Pharmaceutical 11.16 Uni-Bio Science 11.17 Wanbang Biochemical Pharmaceuticals 11.18 Pfizer Inc. 11.19 Chugai Pharmaceutical 11.20 Dragon Pharma
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001716562/buying
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|